Q2 2026 HLS Therapeutics Inc Earnings Call Transcript

Aug 12, 2026 / 02:00 PM GMT

Release Date Price: €2.18 (-2.68%)

Transcript

Key Points

Positve

Cardiovascular portfolio net sales grew 25% year-over-year, driven by double-digit Vascepa growth and strong initial Naleo sales.
Naleo launch is ahead of forecast, with nearly 1,200 new patients started in Q2 and private payer coverage secured for ~80% of privately insured Canadians.
Clozaril patient base in Canada has grown sequentially for five consecutive months, indicating business stabilization.
Strong balance sheet with net debt down 26% from end of 2025, and cash from operations up 14% year-to-date.
Company initiated a share buyback program, returning capital to shareholders while maintaining growth investments.

Negative

Adjusted EBITDA declined ~10% year-over-year due to incremental launch investments for Naleo.
US Clozaril net sales decreased year-over-year, impacted by a challenging comparison and slight demand decline.
Operating expenses increased 10% in Q2 due to Naleo launch costs, pressuring near-term margins.
Provisions rose to $14.6 million, with a cyclical pattern that may impact cash flow timing.
Public reimbursement for Naleo is not expected until first half of 2027, limiting near-term public market access.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

HLS.TO - HLS Therapeutics Inc
Q2 2026 HLS Therapeutics Inc Earnings Call
Aug 12, 2026 / 02:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome to the second quarter of fiscal 2026 financial results conference call for HLS Therapeutics.

At this point, I would like to turn the call over to David Mason in relations for the introductory remarks.

Please go ahead.

Good morning, everyone, and thank you for joining us today.

With me on the call are Craig Million, Chief Executive Officer.

John Hannah, Chief Financial Officer, and Brian Walsh, Chief Operating Officer.

Earlier this morning we issued a news release announcing our financial results for the 3 and 6 months ended June 30, 2026.

This news release along with our MD&A and financial statements is available on our website and on

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.